Alimetry, a gastrointestinal med-tech and digital health start-up, announced today the creation of a new American Medical Association (AMA) Current Procedural Terminology (CPT) III code for Body Surface Gastric Mapping, which will describe its Gastric Alimetry test.
The new CPT III code highlights the growing recognition of Body Surface Gastric mapping and Gastric Alimetry as a significant advance in the diagnosis and management of chronic gastric conditions, including functional dyspepsia, gastroparesis, and chronic nausea and vomiting syndrome. Together, these disorders affect >10% of the US population.
CEO, Greg O’Grady, a Professor of Surgery, and co-founder of Alimetry, said: “Obtaining a CPT III code is a key milestone for Alimetry. Gastric Alimetry is emerging as a next-generation test for patients suffering chronic gastric symptoms, with excellent early adoption in over 30 hospitals and clinics. The new AMA code will accelerate our mission to achieve widespread access for US patients suffering from these disabling disorders.”
The CPT III code comes on the back of Alimetry’s 3rd 510k clearance from the US Food and Drug Administration (FDA) in just 2 years for the Gastric Alimetry System. The latest FDA clearance introduced new features to aid in the diagnosis of gut hypersensitivity and common ‘Gut-Brain-Axis’ disorders, which are often linked to mental wellbeing. Chief Medical Officer Professor Chris Andrews stated: “Gastric symptoms can be complex and are often a diagnostic challenge. Gastric Alimetry combines a wearable sensor with an App-based digital health profiling tool, providing an increasingly powerful feature set that can greatly simplify the diagnostic process. The cloud-based platform also enables us to rapidly learn and improve test performance based on banked data, with an increasing focus on applications in AI.”
In addition to the new CPT Code, Alimetry also announced positive clinical study results, published this month in the American Journal of
Gastroenterology. In the study discussion, the authors concluded that “Gastric Alimetry identified 2.7x more specific patient categories than gastric emptying testing [a standard of care test], with limited overlap between each diagnostic modality, offering a valuable new option in the diagnostic work up of patients with chronic gastroduodenal symptoms”. In addition, Gastric Alimetry data was reported to show “improved correlation with symptoms and psychometrics” compared to existing clinical and research tools.
Gastric Alimetry is commercially available in the United States, the UK and New Zealand. The study article can be accessed in this hyperlink
About Gastric Alimetry
The Gastric Alimetry test measures gastric electrophysiology non-invasively in a clinical setting. Recordings are taken before and after a standard meal, while patients simultaneously log their symptoms into the Gastric Alimetry App. The system performs a high-resolution recording of digestive patterns from the skin surface and delivers clinical reports via the cloud to inform the diagnosis of gastric diseases and support personalized therapy. The Gastric Alimetry system is indicated as an aid to diagnosis of various gastric disorders, including functional dyspepsia, gastroparesis and chronic nausea and vomiting disorders, which affect >10% of the US population and impact billions of dollars in healthcare expenses.
About AMA CPT III Codes
AMA CPT III codes are temporary codes assigned to emerging medical technologies and procedures. These codes facilitate data collection and assessment, aiding in the validation and reimbursement of new services. Obtaining a CPT III code, such as for Alimetry's Gastric Alimetry test, is a vital step towards recognizing its clinical relevance and supporting its integration into healthcare practices. The new CPT III code number is 0868T and it is effective from July 1, 2024.
About Alimetry
Alimetry is a medtech and digital health start-up focused on improving the care of patients with chronic gastrointestinal symptoms. Spun out of the
University of Auckland in 2019 from a centre of excellence in digestive diseases, the company was founded by Professor Gregory O’Grady (CEO) and Dr. Armen Gharibans (CTO), leveraging a decade of award-winning science. Alimetry is dedicated to advancing gastrointestinal health through innovative diagnostic solutions, aiming to enhance the quality of life for patients worldwide. For more information see www.alimetry.com